CIBC Bancorp USA’s Beam Therapeutics BEAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$292K Buy
11,947
+4,329
+57% +$121K ﹤0.01% 1702
2026
Q2
$261K Buy
+7,618
New +$230K ﹤0.01% 1624
2025
Q3
$247K Buy
+10,192
New +$203K ﹤0.01% 1167

Other funds holding BEAM

CIBC Bancorp USA's BEAM Position: Q3 2026 in Review

CIBC Bancorp USA increased its Beam Therapeutics (BEAM) stake by 57% in Q3 2026, buying an estimated $121K and bringing the position to 11,947 shares worth $292K. The position accounts for ﹤0.01% of the portfolio, ranked #1702.

CIBC Bancorp USA first reported a position in BEAM in Q3 2025 and has held it in 3 quarters since. 264 funds tracked by Wall St. Rank hold BEAM as of Q3 2026.

  • CIBC Bancorp USA held 11,947 shares of Beam Therapeutics worth $292K as of Q3 2026.
  • CIBC Bancorp USA bought 4,329 Beam Therapeutics shares in Q3 2026, an estimated $121K.
  • Beam Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1702 holding.
  • CIBC Bancorp USA first reported a position in Beam Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 264 funds tracked by Wall St. Rank held Beam Therapeutics as of Q3 2026.

Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.